Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 508

1.

Characterization of circulating DNA in plasma of patients after allogeneic bone grafting.

Solakoglu Ö, Steinbach B, Götz W, Heydecke G, Pantel K, Schwarzenbach H.

Clin Oral Investig. 2019 Mar 3. doi: 10.1007/s00784-019-02867-3. [Epub ahead of print]

PMID:
30826920
2.

Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer.

Müller V, Oliveira-Ferrer L, Steinbach B, Pantel K, Schwarzenbach H.

Mol Oncol. 2019 Feb 25. doi: 10.1002/1878-0261.12472. [Epub ahead of print]

3.

Liquid biopsy and minimal residual disease - latest advances and implications for cure.

Pantel K, Alix-Panabières C.

Nat Rev Clin Oncol. 2019 Feb 22. doi: 10.1038/s41571-019-0187-3. [Epub ahead of print] Review.

PMID:
30796368
4.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer EF, Fehm T, Müller V.

Sci Rep. 2019 Feb 19;9(1):2318. doi: 10.1038/s41598-018-37259-2.

5.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
6.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S.

Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32163. [Epub ahead of print]

PMID:
30694523
7.

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma.

Riethdorf S, Hildebrandt L, Heinzerling L, Heitzer E, Fischer N, Bergmann S, Mauermann O, Waldispühl-Geigl J, Coith C, Schön G, Peine S, Schuler G, Speicher MR, Moll I, Pantel K.

Clin Chem. 2019 Mar;65(3):462-472. doi: 10.1373/clinchem.2018.297028. Epub 2019 Jan 9.

PMID:
30626636
8.

Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility.

Pantel K, Hille C, Scher HI.

Clin Chem. 2019 Jan;65(1):87-99. doi: 10.1373/clinchem.2018.287102. Review.

PMID:
30602476
9.

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease.

Hanssen A, Riebensahm C, Mohme M, Joosse SA, Velthaus JL, Berger LA, Bernreuther C, Glatzel M, Loges S, Lamszus K, Westphal M, Riethdorf S, Pantel K, Wikman H.

Cancers (Basel). 2018 Dec 19;10(12). pii: E527. doi: 10.3390/cancers10120527.

10.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.

Lange T, Oh-Hohenhorst SJ, Joosse SA, Pantel K, Hahn O, Gosau T, Dyshlovoy SA, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U.

Sci Rep. 2018 Dec 3;8(1):17535. doi: 10.1038/s41598-018-35695-8.

11.

Liquid biopsy: novel technologies and clinical applications.

Reimers N, Pantel K.

Clin Chem Lab Med. 2019 Feb 25;57(3):312-316. doi: 10.1515/cclm-2018-0610.

12.

Liquid biopsies.

Lianidou E, Pantel K.

Genes Chromosomes Cancer. 2019 Apr;58(4):219-232. doi: 10.1002/gcc.22695. Review.

PMID:
30382599
13.

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes.

Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy PJ, Assou S, Assenat E, Pantel K, Alix-Panabières C.

Sci Rep. 2018 Oct 29;8(1):15931. doi: 10.1038/s41598-018-34365-z.

14.

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group.

J Natl Cancer Inst. 2018 Oct 11. doi: 10.1093/jnci/djy152. [Epub ahead of print]

PMID:
30312434
15.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H.

BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.

16.

ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer.

Nastały P, Filipska M, Morrissey C, Eltze E, Semjonow A, Brandt B, Pantel K, Bednarz-Knoll N.

Transl Res. 2019 Jan;203:49-56. doi: 10.1016/j.trsl.2018.08.007. Epub 2018 Sep 12.

PMID:
30287243
17.

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A.

Breast Cancer Res Treat. 2019 Jan;173(1):155-165. doi: 10.1007/s10549-018-4972-y. Epub 2018 Oct 1.

PMID:
30276763
18.

Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer.

Woestemeier A, Ghadban T, Riethdorf S, Harms-Effenberger K, Konczalla L, Uzunoglu FG, Izbicki JR, Pantel K, Bockhorn M, Reeh M.

Anticancer Res. 2018 Oct;38(10):5665-5669. doi: 10.21873/anticanres.12902.

PMID:
30275185
19.

Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.

Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.

Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.

PMID:
30265376
20.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8. No abstract available.

PMID:
30205165
21.

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.

Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H.

Sci Rep. 2018 Aug 28;8(1):12974. doi: 10.1038/s41598-018-31108-y.

22.

Exosomal microRNAs as tumor markers in epithelial ovarian cancer.

Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K, Schwarzenbach H.

Mol Oncol. 2018 Nov;12(11):1935-1948. doi: 10.1002/1878-0261.12371. Epub 2018 Oct 9.

23.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.

PMID:
30094535
24.

miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes.

Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier CH, Bachelier R, Allioli N, Hong SS, Bartkowiak K, Pantel K, Clézardin P.

Cancer Res. 2018 Sep 15;78(18):5259-5273. doi: 10.1158/0008-5472.CAN-17-3058. Epub 2018 Jul 24.

PMID:
30042152
25.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.

Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, Fabre JM, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K.

Clin Chem. 2018 Oct;64(10):1505-1512. doi: 10.1373/clinchem.2018.289819. Epub 2018 Jul 20.

PMID:
30030273
26.

Abstracts from the 11th International Symposium on Minimal Residual Disease, 3-5 May 2018, Montpellier, France.

Alix-Panabières C, Pantel K.

Clin Exp Metastasis. 2018 Mar;35(3):167-217. doi: 10.1007/s10585-018-9911-0. No abstract available.

PMID:
30008067
27.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer EF, Fehm T, Müller V.

Breast Cancer Res Treat. 2018 Nov;172(1):93-104. doi: 10.1007/s10549-018-4882-z. Epub 2018 Jul 12.

PMID:
30003393
28.

11th International Symposium on Minimal Residual Cancer (ISMRC): 3-5 May 2018, Montpellier, France.

Alix-Panabières C, Pantel K.

Clin Exp Metastasis. 2018 Mar;35(3):87-90. doi: 10.1007/s10585-018-9909-7. Epub 2018 Jul 6. No abstract available.

PMID:
29980892
29.

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.

Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP, Fasching PA, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Janni W, Rack B, Scholz C; SUCCESS Study Group.

Breast Cancer Res Treat. 2018 Oct;171(3):571-580. doi: 10.1007/s10549-018-4856-1. Epub 2018 Jun 21.

PMID:
29931425
30.

Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation.

Schneider T, Kemmling A, Schroeder J, Pantel K, Glatzel M, Schoen G, Mohme M, Fiehler J, Gellißen S.

Front Neurol. 2018 May 30;9:391. doi: 10.3389/fneur.2018.00391. eCollection 2018.

31.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY.

Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211.

PMID:
29893791
32.

Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases.

Le UT, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi JT, Schmid S.

Sci Rep. 2018 Jun 8;8(1):8751. doi: 10.1038/s41598-018-26410-8.

33.

Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy."

Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M.

Urol Oncol. 2018 Jul;36(7):347-348. doi: 10.1016/j.urolonc.2018.05.013. Epub 2018 Jun 5.

PMID:
29880457
34.

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization.

Chen S, El-Heliebi A, Schmid J, Kashofer K, Czyż ZT, Polzer BM, Pantel K, Kroneis T, Sedlmayr P.

J Vis Exp. 2018 May 15;(135). doi: 10.3791/56394.

35.

Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases.

Gerstenberger W, Wrage M, Kettunen E, Pantel K, Anttila S, Steurer S, Wikman H.

Anal Cell Pathol (Amst). 2018 Apr 10;2018:8651790. doi: 10.1155/2018/8651790. eCollection 2018.

36.

Clinical utility of circulating non-coding RNAs - an update.

Anfossi S, Babayan A, Pantel K, Calin GA.

Nat Rev Clin Oncol. 2018 Sep;15(9):541-563. doi: 10.1038/s41571-018-0035-x. Review.

PMID:
29784926
37.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer EF, Witzel I, Müller V.

BMC Cancer. 2018 May 8;18(1):541. doi: 10.1186/s12885-018-4282-0.

38.

Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S.

Cancer Res. 2018 Jun 15;78(12):3220-3232. doi: 10.1158/0008-5472.CAN-17-3415. Epub 2018 Apr 19.

PMID:
29674477
39.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
40.

Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells.

Follain G, Osmani N, Azevedo AS, Allio G, Mercier L, Karreman MA, Solecki G, Garcia Leòn MJ, Lefebvre O, Fekonja N, Hille C, Chabannes V, Dollé G, Metivet T, Hovsepian F, Prudhomme C, Pichot A, Paul N, Carapito R, Bahram S, Ruthensteiner B, Kemmling A, Siemonsen S, Schneider T, Fiehler J, Glatzel M, Winkler F, Schwab Y, Pantel K, Harlepp S, Goetz JG.

Dev Cell. 2018 Apr 9;45(1):33-52.e12. doi: 10.1016/j.devcel.2018.02.015.

PMID:
29634935
41.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells.

Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S.

Haematologica. 2018 Jun;103(6):939-948. doi: 10.3324/haematol.2017.181354. Epub 2018 Mar 22.

42.

Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.

Effenberger KE, Schroeder C, Hanssen A, Wolter S, Eulenburg C, Tachezy M, Gebauer F, Izbicki JR, Pantel K, Bockhorn M.

Clin Cancer Res. 2018 Jun 15;24(12):2844-2850. doi: 10.1158/1078-0432.CCR-18-0120. Epub 2018 Mar 20.

PMID:
29559560
43.

Advances in liquid biopsy approaches for early detection and monitoring of cancer.

Babayan A, Pantel K.

Genome Med. 2018 Mar 20;10(1):21. doi: 10.1186/s13073-018-0533-6.

44.

Prostate cancer: Circulating tumour cells in prostate cancer.

Hille C, Pantel K.

Nat Rev Urol. 2018 May;15(5):265-266. doi: 10.1038/nrurol.2018.25. Epub 2018 Mar 6. No abstract available.

PMID:
29508846
45.

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.

Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W, Friedl TWP; SUCCESS Study Group.

Oncol Res Treat. 2018;41(3):93-98. doi: 10.1159/000485566. Epub 2018 Feb 27.

46.

Clinical applications of the CellSearch platform in cancer patients.

Riethdorf S, O'Flaherty L, Hille C, Pantel K.

Adv Drug Deliv Rev. 2018 Feb 1;125:102-121. doi: 10.1016/j.addr.2018.01.011. Epub 2018 Feb 2. Review.

PMID:
29355669
47.

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.

Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Burwinkel B.

Breast Cancer Res Treat. 2018 May;169(1):69-82. doi: 10.1007/s10549-018-4666-5. Epub 2018 Jan 16.

PMID:
29340881
48.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells.

El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges TM, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P.

Clin Chem. 2018 Mar;64(3):536-546. doi: 10.1373/clinchem.2017.281295. Epub 2018 Jan 4.

49.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun HT, Coxon A, Lee B, Kang Y.

Cancer Cell. 2017 Dec 11;32(6):731-747.e6. doi: 10.1016/j.ccell.2017.11.002.

50.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Sci Rep. 2017 Dec 11;7(1):17307. doi: 10.1038/s41598-017-17514-8.

Supplemental Content

Loading ...
Support Center